Post Profile

Ceritinib provides longer PFS than chemo in phIII trial of ALK rearranged lung cancer

(European Society for Medical Oncology) Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study presented today at the ESMO 2016 Congress in Copenhagen.
read more


Related Posts

Medical News Today: Study finds drug improves survival for patients with non-small cell lung cancer

Health : Medical News Today

A new phase 3 trial finds that overall survival is longer for patient with non-small cell lung cancer treated with the drug nivolumab compared with chemotherapy drug docetaxel.

Different Approach Suggested After Progression In NSCLC Patients

Health : Medical News Today

Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR...

ALK Rearrangement In Lung Cancer Patients Detected By Inexpensive Method

Health : Medical News Today

A relatively simple and inexpensive method may be used to determine whether a lung cancer patient is a candidate for crizotinib therapy, according to research published in the August issue of the Journal of Thoracic Oncology, the of...

New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population

Health : Medical News Today

Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, ...

A new kind of treatment is working better than chemotherapy in some lung cancer patients (BMY, MRK)

Business & Finance : Business Insider: Money Game

For people with advanced forms of lung cancer, chemotherapy might not be the only — or even the best — option. The drug, marketed as Keytruda, is one of a new set of drugs called immunotherapy. The drug targets the programmed cell d...


Copyright © 2016 Regator, LLC